Instead, here we provide evidence that these pathways are interconnected and that the inhibitory effects on mTOR exerted by Everolimus include a negative regulation of NFkB, thus explaining the reduced secretion of M-CSF, IL-1β and IL-6 by BC cells after mTOR inhibition. The gene discussed is MTOR; the disease is breast cancer.